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DOI 10.1186/s12917-015-0448-zRESEARCH ARTICLE Open AccessmRNA expression of genes involved in
inflammation and haemostasis in equine
fibroblast-like synoviocytes following
exposure to lipopolysaccharide, fibrinogen
and thrombin
Stine Mandrup Andreassen1*, Lise C. Berg2, Søren Saxmose Nielsen3, Annemarie T. Kristensen2 and Stine Jacobsen1Abstract
Background: Studies in humans have shown that haemostatic and inflammatory pathways both play important
roles in the pathogenesis of joint disease. The aim of this study was to assess mRNA expression of haemostatic
and inflammatory factors in cultured equine fibroblast-like synoviocytes exposed to lipopolysaccharide (LPS),
fibrinogen and thrombin. Synovial membranes were collected from metacarpo-phalangeal joints of 6 skeletally
mature horses euthanized for non-orthopaedic reasons. Passage 4 fibroblast-like synoviocytes were left non-treated or
treated with either 0.1 μg/ml LPS, 5 mg/ml fibrinogen or 5 U/ml thrombin and harvested at time points 0, 6, 24 and 48 h.
mRNA expression of serum amyloid A (SAA), interleukin-6 (IL-6), monocyte chemotactic protein 1 (MCP-1), tissue factor
(TF), plasminogen activator inhibitor 1 (PAI-1), urokinase plasminogen activator (uPA), vascular endothelial growth factor
(VEGF) and protease activator receptor 1 (PAR-1) was assessed using quantitative real time reverse transcriptase PCR.
Results: LPS caused a significant increase in mRNA expression of SAA, IL-6, MCP-1 and uPA, and a decrease in TF, PAI-1
and PAR-1 when compared to non-treated cells. Treatment with thrombin resulted in increased mRNA expression of SAA,
IL-6, MCP-1 and PAI-1, and a decreased PAR-1 expression compared to non-treated cells. The fibrinogen-treated
synoviocytes showed significantly increased mRNA expression of IL-6, MCP-1, TF and PAI-1, and decreased PAR-1
expression compared to non-treated cells.
Conclusion: LPS, fibrinogen and thrombin induced an increased gene expression of inflammatory markers in
isolated equine fibroblast-like synoviocytes. LPS caused changes in gene expression promoting increased fibrinolysis,
while fibrinogen and thrombin changed the gene expression resulting potentially in reduced fibrinolysis. Overall, it
appeared that both inflammatory and haemostatic stimuli affected expression of genes involved in inflammatory and
haemostatic pathways, supporting their importance in equine joint diseases.
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Joint diseases such as osteoarthritis (OA), osteochondrosis
dissecans and septic arthritis affect horses regularly and
are common causes of lameness and reduced performance
[1–3]. The pathogenesis of joint disease is complex, but an
inflammatory reaction is a common characteristic and has
been studied extensively in the horse [4–6]. Increased
levels of inflammatory components such as leukocytes,
serum amyloid A (SAA), interleukin (IL)-1β, IL-6, tumour
necrosis factor α (TNF- α), and matrix metalloproteinases
have been demonstrated in horses with naturally occur-
ring and experimentally induced septic arthritis and
OA [4, 7–9]. Fibroblast-like synoviocytes are known to
contribute to progression of joint disease [10], and in
the pathogenesis of OA it is recognised that fibroblast-like
synoviocytes participate by producing proinflammatory
cytokines and cartilage-degrading mediators [11–13].
Equine septic arthritis and rheumatoid arthritis (RA) in
humans are both characterized as severe inflammatory
conditions showing similar pathologic occurrences such as
intra-articular cell recruitment and synoviocyte driven
cytokine release [4, 6, 14–16].
Recent research in human joint disease has indicated
that haemostatic pathways also play an important part in
the pathogenesis of joint disease, and that activation of
inflammation and haemostasis are closely related [17].
Haemostatic components are not only present in the ini-
tial stages of an intra-articular inflammatory event, it also
seems that the two systems interact throughout the dis-
ease process [18]. Studies in humans and rodents have
shown that both coagulation and fibrinolysis are activated
intra-articularly in RA and OA [15, 19].
To our knowledge the potential co-occurrence of
intra-articular expression of inflammatory and haemostasis
markers in the horse has not previously been investigated.
Lipopolysaccharide (LPS) has been described to elicit both
in vivo and in vitro arthritic inflammatory responses
[7, 16, 20]. Thrombin, a key proteinase in the process of
fibrin formation, has been reported to be elevated in syn-
ovial fluid from humans with OA and RA [21], and when
synoviocytes derived from patients with RA were exposed
to thrombin, their production of IL-6 increased [14, 22].
Fibrinogen, a large coagulant protein synthesized by he-
patocytes and normally absent or present in very low con-
centration in non-diseased synovial fluid, has been detected
in elevated concentrations in synovial fluid from human
OA patients [23]. In human synovial fibroblasts and pan-
creatic stellate cells fibrinogen has been found to induce
inflammatory reactions [24, 25]. Fibrin(ogen) may regu-
late progression of inflammation in joint disease and has
the potential to maintain inflammation [18, 24]. It has
been reported that fibrinolysis is needed to resolve joint
inflammation [15]. Fibrin aggregates were found in syn-
ovial fluid in rabbits within 24 h of antigen-inducedarthritis [26], and in horses recently published papers have
shown for the first time that d-dimer, an end-product of fi-
brinolysis, is present in increased concentrations in syn-
ovial fluid in joint disease [27, 28]. This indicates that,
along with inflammation, haemostasis is activated and
may play a role in the pathogenesis of joint disease in
horses and other species.
The overall aim of this study was to further our un-
derstanding of the events taking place in the early
stages of joint disease by studying effects of inflammatory
and haemostatic stimuli on gene expression in cultured
fibroblast-like synoviocytes. The specific objectives were to
investigate the effects of LPS, fibrinogen and thrombin on
the expression of genes representing acute inflammation
(IL-6, SAA, monocyte chemotactic protein-1 [MCP-1]),
initiation of haemostasis (tissue factor [TF]), fibrinolysis
(urokinase plasminogen activator [uPA], plasminogen
activator inhibitor-1 [PAI-1]), angiogenesis (vascular endo-
thelial growth factor [VEGF]) and thrombin-binding re-
ceptor (proteinase activated receptor-1 [PAR-1]) in equine
fibroblast-like synoviocytes.
Results
Cell morphology became increasingly more uniform
across passages. In the first passage, round and amorphous
cells without pseudopods—resembling macrophage-like
synoviocytes (type A cells)—were occasionally observed.
In the third and fourth passage, cells were homogenous
and had large pseudopods, characteristics of fibroblast-like
synoviocytes (type B cells) [29, 30]. After thawing and at
every passage cell viability was assessed to > 95 % (data
not shown). Following, results are described according to
treatments, and shown in figures according to outcome
parameter (Figs. 1, 2, and 3: acute inflammation (SAA,
IL-6, MCP-1); Fig. 4: initiation of haemostasis (TF);
Figs. 5 and 6: fibrinolysis (uPA, PAI-1); Fig. 7: angiogenesis
(VEGF) and Fig. 8: thrombin-binding receptor (PAR-1)).
Non-treated synoviocytes
For the non-treated synoviocytes there were no statistically
significant changes in expression of IL-6, PAI-1 and uPA
over time (Figs. 2, 5, 6). The expression of VEGF and PAR-
1 increased significantly over time with expression levels at
every time point being significantly higher than expression
levels at 0 h (Figs. 7 and 8). Expression levels of SAA,
MCP-1 and TF were significantly higher than expression
levels at 0 h on one or two time points (SAA: 6 h, MCP-1:
24 h, TF: 24 and 48 h) (Figs. 1, 3 and 4).
Treatment with LPS
In synoviocytes treated with LPS mRNA expression of
SAA, IL-6 and MCP-1 was significantly higher than expres-
sion at 0 h at every time point (6, 24, and 48 h). Also, their
expression levels were significantly higher than expression
Fig. 1 mRNA expression levels of serum amyloid A (SAA) from equine fibroblast-like synoviocytes shown as log-transformed GAPDH-normalized
relative ratios. Error bars show SE centered on the mean. Raw data are plotted with open symbols. Asterisks designate significant difference from
non-treated within a time point (* = p < 0.05; ** = p < 0.01 and *** = p < 0.001). Superscript letters designate significant differences from time point
0 within a treatment (a = p < 0.05; b = p < 0.01 and c = p < 0.001). Treatments of the equine synovial fibroblast are coloured (Non-treated = red;
fibrinogen = blue; LPS = green; thrombin = orange)
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time point (Figs. 1, 2 and 3). Expression of VEGF showed
statistically significant increases over time compared to time
point 0, but no differences were detected between the LPS
stimulated synoviocytes and the non-treated controls
(Fig. 7). Expression of TF, PAI-1 and uPA showed intermit-
tent significant increases relative to 0 h after LPS treatment
(Figs. 4, and 6). TF, PAI-1 and PAR-1 mRNA expression
levels were significantly lower than expression levels in the
corresponding non-treated control at 24 and/or 48 h in re-
sponse to LPS treatment (Figs. 4, 5 and 8). uPA mRNAFig. 2 mRNA expression levels of interleukin-6 (IL-6) from equine fibroblast-lik
ratios. Error bars show SE centered on the mean. Raw data are plotted with o
within a time point (* = p < 0.05; ** = p < 0.01 and *** = p < 0.001). Supersc
a treatment (a = p < 0.05; b = p < 0.01 and c = p< 0.001). Treatments of the equ
LPS = green; thrombin = orange)expression levels increased significantly at 6 h after treat-
ment compared to non-treated control (Fig. 6).
Treatment with fibrinogen
In fibrinogen-treated synoviocytes, mRNA expression of
SAA increased significantly over time, but expression
levels were not significantly different from the corre-
sponding non-treated control (Fig. 1). mRNA expression
of IL-6, MCP-1, TF and PAI-1 in fibrinogen treated
synoviocytes was significantly increased at one or more
time points relative to 0 h, and their mRNA expressione synoviocytes shown as log-transformed GAPDH-normalized relative
pen symbols. Asterisks designate significant difference from non-treated
ript letters designate significant differences from time point 0 within
ine synovial fibroblast are coloured (Non-treated = red; fibrinogen = blue;
Fig. 3 mRNA expression levels of monocyte chemotactic protein-1 (MCP-1) from equine fibroblast-like synoviocytes shown as log-transformed
GAPDH-normalized relative ratios. Error bars show SE centered on the mean. Raw data are plotted with open symbols. Asterisks designate significant
difference from non-treated within a time point (* = p < 0.05; ** = p < 0.01 and *** = p < 0.001). Superscript letters designate significant differences
from time point 0 within a treatment (a = p < 0.05; b = p < 0.01 and c = p < 0.001). Treatments of the equine synovial fibroblast are coloured
(Non-treated = red; fibrinogen = blue; LPS = green; thrombin = orange)
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non-treated control at one or two time points after
treatment (IL-6: 48 h, MCP-1: 6 and 48 h, TF: 6 h and
PAI-1: 24 h; Figs. 2, 3, 4 and 5). mRNA expression of
uPA, VEGF and PAR-1 did not change significantly in
response to the fibrinogen treatment compared to non-
treated control. VEGF and PAR-1 did show significant
increases compared to time point 0 at two or three
time points (Figs. 6, 7 and 8).Fig. 4 mRNA expression levels of tissue factor (TF) from equine fibroblast-l
ratios. Error bars show SE centered on the mean. Raw data are plotted with o
within a time point (* = p < 0.05; ** = p < 0.01 and *** = p < 0.001). Supers
a treatment (a = p < 0.05; b = p < 0.01 and c = p< 0.001). Treatments of the equ
LPS = green; thrombin = orange)Treatment with thrombin
Thrombin treatment of equine synoviocytes resulted in
significantly higher mRNA expression of SAA, IL-6 and
MCP-1 compared to non-treated controls and to expres-
sion at 0 h at every time point (6, 24 and 48 h; Figs. 1, 2
and 3). mRNA expression of PAI-1 was significantly in-
creased at 6 h after thrombin treatment compared to
non-treated controls (Fig. 5). mRNA expression of PAR-1
was significantly decreased at 24 and 48 h after treatmentike synoviocytes shown as log-transformed GAPDH-normalized relative
pen symbols. Asterisks designate significant difference from non-treated
cript letters designate significant differences from time point 0 within
ine synovial fibroblast are coloured (Non-treated = red; fibrinogen = blue;
Fig. 5 mRNA expression levels of plasminogen activator inhibitor-1 (PAI-1) from equine fibroblast-like synoviocytes shown as log-transformed
GAPDH-normalized relative ratios. Error bars show SE centered on the mean. Raw data are plotted with open symbols. Asterisks designate significant
difference from non-treated within a time point (* = p < 0.05; ** = p < 0.01 and *** = p < 0.001). Superscript letters designate significant differences from
time point 0 within a treatment (a = p < 0.05; b = p < 0.01 and c = p < 0.001). Treatments of the equine synovial fibroblast are coloured (Non-treated = red;
fibrinogen = blue; LPS = green; thrombin = orange)
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thrombin treatment mRNA expression of TF, PAI-1, uPA,
VEGF and PAR-1 were significantly increased compared
to time point 0 (Figs. 4, 5 and 8).
Discussion
The results of the study showed that LPS exerted its
well-described proinflammatory effects [31] in isolated
equine synoviocytes by increasing expression of SAA,
IL-6 and MCP-1. Moreover, LPS induced alteration ofFig. 6 mRNA expression levels of urokinase plasminogen activator (uPA) fro
relative ratios. Error bars show SE centered on the mean. Raw data are plot
non-treated within a time point (* = p < 0.05; ** = p < 0.01 and *** = p < 0.0
0 within a treatment (a = p < 0.05; b = p < 0.01 and c = p < 0.001). Treatmen
fibrinogen = blue; LPS = green; thrombin = orange)expression of factors affecting the fibrinolytic potential
of the synoviocytes (up-regulation of uPA and down-
regulating PAI-1) and caused a decrease in mRNA expres-
sion of TF. Thrombin treatment also induced inflammatory
changes by increased expression of SAA, IL-6 and MCP-1,
but decreased fibrinolysis by an early increase in PAI-1. Fi-
brinogen exposure also caused an increase in expression of
inflammatory markers (IL-6 and MCP-1). In contrast to
LPS, fibrinogen induced increased mRNA expression of
TF and PAI-1 in the synoviocytes—changes that havem equine fibroblast-like synoviocytes shown as GAPDH-normalized
ted with open symbols. Asterisks designate significant difference from
01). Superscript letters designate significant differences from time point
ts of the equine synovial fibroblast are coloured (Non-treated = red;
Fig. 7 mRNA expression levels of vascular endothelial growth factor (VEGF) from equine fibroblast-like synoviocytes shown as log-transformed
GAPDH-normalized relative ratios. Error bars show SE centered on the mean. Raw data are plotted with open symbols. Asterisks designate significant
difference from non-treated within a time point (* = p < 0.05; ** = p < 0.01 and *** = p < 0.001). Superscript letters designate significant differences from
time point 0 within a treatment (a = p < 0.05; b = p < 0.01 and c = p < 0.001). Treatments of the equine synovial fibroblast are coloured (Non-treated = red;
fibrinogen = blue; LPS = green; thrombin = orange)
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and inhibit fibrinolysis (PAI-1). All three treatments de-
creased the mRNA expression of PAR-1.
A common characteristic of several joint conditions is
inflammation, and studies have shown its importance in
development and healing of disease processes [15, 17, 18].
Lately haemostatic reactions have obtained interest, since
upregulation of factors involved in coagulation and fi-
brinolytic pathways has been shown to occur intra-
articularly in mice with antigen-induced arthritis [19] and
in humans with naturally occurring arthritis [15, 23]. ItFig. 8 mRNA expression levels of proteinase activated receptor 1 (PAR-1) from
GAPDH-normalized relative ratios. Error bars show SE centered on the mean. R
difference from non-treated within a time point (* = p < 0.05; ** = p < 0.01 and
time point 0 within a treatment (a = p < 0.05; b = p < 0.01 and c = p< 0.001). Tr
fibrinogen = blue; LPS = green; thrombin = orange)thus seems, just as in systemic reactions, that both inflam-
matory and haemostatic pathways are activated and likely
interlinked in the joint cavity [17, 18]. One link between
inflammation and haemostasis is fibrinogen, which is an
acute phase protein upregulated during inflammation, but
also serves a crucial role in haemostasis. Fibrinogen has
been shown to serve as inducer and regulator of inflam-
matory reactions in joint diseases in humans and rodents
[17, 18, 24, 32]. Thrombin is another link between inflam-
mation and haemostasis. While thrombin has traditionally
been thought of as a procoagulant through its inductionequine fibroblast-like synoviocytes shown as square root-transformed
aw data are plotted with open symbols. Asterisks designate significant
*** = p < 0.001). Superscript letters designate significant differences from
eatments of the equine synovial fibroblast are coloured (Non-treated = red;
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inducer of production of inflammatory biomolecules such
as MCP-1 and IL-6 and activator of leukocytes [14, 33]. In
horses, inflammatory changes in joints with spontaneous
or experimentally-induced arthritis are well-described
[20, 34, 35]. In contrast, only few studies have attempted
to assess haemostatic factors intra-articularly in horses.
Two recent studies have described increases in d-dimer in
synovial fluid of horses with joint disease [28, 36], indicat-
ing that fibrinolysis is active in the intra-articular compart-
ment of horses with joint inflammation. It is thus possible
that the cross-talk between inflammation and haemostasis
suggested as a hallmark of human joint disease [37, 38]
may also be at play in horses.
LPS is a well-known inflammatory inducer, and it was
therefore not surprising that it caused an up-regulation
of mRNA expression of the inflammatory markers SAA
and IL-6 starting at 6 h and continuing till the end of
the study (48 h). Similar results have been found in
other in vitro studies showing LPS-induced increases in
SAA mRNA expression in chicken synovial fibroblast
[30] and in IL-6 mRNA expression in equine and human
synoviocytes [14, 16]. LPS exposure also caused the
equine synoviocytes to express MCP-1 mRNA. While
this to our knowledge is the first time that MCP-1 is
described in horses, similar results have been found in
IL-1β-treated human synoviocytes [39] and in mice
with haemophilic synovitis [40]. MCP-1 serves to recruit
mononuclear cells to the joint compartment [39–41], and
MCP-1 has been suggested to correlate with the degree of
inflammatory changes in human synovial membrane [42].
Thrombin stimulation caused significant increases in
mRNA expressions of the three inflammatory markers of
this study (SAA, IL-6 and MCP-1) in the synoviocytes, re-
sembling the response observed after LPS stimulation.
Thrombin-induced IL-6 production has previously been
shown in human synovial fibroblasts [14], and MCP-1
induction by thrombin has been shown in endothelial
cells [43] and MCP-1 was found elevated in synovial
fluid from haemophilic mice [40]. Proinflammatory ef-
fects of thrombin have thus been demonstrated across
species and tissues.
The inflammation-inducing potential of fibrinogen is less
well described than that of LPS. In the present study,
fibrinogen induced a significant increase in mRNA ex-
pression of IL-6 and MCP-1 after 48 and 6 h of stimulation,
respectively. In species other than the horse, fibrinogen ex-
posure has been described to cause inflammatory changes:
increased IL-6 concentrations were found in culture super-
natant from fibrinogen-treated human pancreatic stellate
cells [25], and fibrinogen induced increases in MCP-1
expression was shown in endothelial cells of humans and
pigs [44, 45]. In articular tissue, fibrinogen exposure has
been shown to exert proinflammatory functions. Humansynovial fibroblasts cultured in vitro in the presence of fi-
brinogen had increased expression of intercellular adhesion
molecules (ICAM) and interleukin-8 (IL-8) [24]. By in-
creasing expression of ICAM, IL-8, and MCP-1 fibrinogen
may serve to attract and retain leukocytes intra-articularly,
but at this stage the exact effects of fibrinogen in the intra-
articular compartment are unknown.
Factors involved in haemostasis pathways were induced
in equine synoviocytes after LPS, thrombin and fibrinogen
exposure. Fibrinogen-treated synoviocytes showed in-
creased mRNA expression of TF at 6 h and thereafter a
gradual decline. In contrast, LPS-treatment decreased the
mRNA expression of TF at 48 h. This is surprising and
interesting, since LPS stimulation has been found to
increase TF in equine peritoneal macrophages [46]. In
vivo, a gradual increase in TF mRNA expression over
7 days has been demonstrated in mice with antigen-
induced arthritis [19] and increased TF activities along
with increased fibrinogen concentrations have been
found in inflamed synovial fluid from human arthritis
[23]. TF initiates cell based haemostasis [47] resulting
in thrombin formation [48], but TF is also described as
a link between inflammation and haemostasis [23]. TF
has been suggested to play an active role in attraction
of monocytes to the synovial membrane [49], and a signifi-
cant correlation between synovial fluid TF concentrations
and leukocyte counts has been demonstrated [15]. To fur-
ther characterize and understand the synovial TF response
in horses, the in vitro results presented here need to be
corroborated by in vivo data.
The balance between uPA and PAI-1 determines the
fibrinolytic activity in the joint [50, 51]. The LPS-treated
equine synoviocytes in this study showed a significant
increase in uPA mRNA expression at 6 h followed by a
steady decline, and a gradual decrease in PAI-1 mRNA
expression throughout the 48-h study period, which
would increase fibrinolysis. In contrast, fibrinogen- and
thrombin-treated synoviocytes did not show changes in
uPA mRNA expression, while mRNA expression of PAI-1
increased significantly at 24 and 6 h, respectively. Taken
together, this suggests that an inflammatory stimulus in-
creases the fibrinolytic capacity of equine synoviocytes first
by an uPA increase and then a PAI-1 decrease, whereas
the haemostatic proteins fibrinogen and thrombin appear
to inhibit the fibrinolytic capacity of equine synoviocytes
by upregulation of PAI-1. In human synovial tissue ob-
tained from patients with OA and RA both uPA and
3B2 thyc=10?>PAI-1 mRNA expression was increased
[32], and in mice with antigen-induce arthritis uPA
mRNA expression in synovial tissue quickly increased
and peaked around 4 h, while PAI-1 was increased in the
first 3 days after induction of arthritis [19]. These findings
seemingly suggest that inflamed joints develop a pro- or
hyper-coagulable state with tendency to produce and clot
Andreassen et al. BMC Veterinary Research  (2015) 11:141 Page 8 of 12more fibrinogen [19]. If the same is true for the horse, the
results of this study indicate that fibrinolytic pathways are
intact in initial inflammatory arthritis, and when fibrino-
gen and thrombin accumulation occurs in the joint cavity,
coagulation increases and fibrinolysis decreases, making
the joint potentially vulnerable to fibrin deposition and its
deleterious effects.
PAR-1, a trans-membrane receptor for thrombin and
other proteinases [52], showed significantly lower expres-
sion at 24 and 48 h after all three treatments compared to
the non-treated controls. LPS caused the most down-
regulation of PAR-1 expression. PAR-1 knockout mice
have shown less clinical symptoms in antigen-induced
arthritis compared to wild type mice [53], and PAR-1 has
also been demonstrated in human RA synovial fibroblasts
[54, 55]. These results indicate that PAR-1 plays a role in
joint disease processes [22]. Increased synovial fibroblast
proliferation [54] and increased mRNA expression in syn-
ovial fibroblast of inflammatory cytokines IL-6, IL-8 and
TNF-α have been shown to be mediated through PAR-1
[14, 56]. Whether inflammation up- or down-regulates
expression of PAR-1 in articular tissues is not currently
clear. Opposite to our results, PAR-1 has been found in
increased levels in inflamed human muscle cells [57]
and infected murine smooth muscle cell [58], and
thrombin and LPS have been shown to induce PAR-1
mRNA expression in endothelial cells [59] and in rat
astrocytes [60]. In accordance with the findings of our
study, decreasing levels of PAR-1 mRNA has been
found in ischemic rat brain [61] and after TNF-α
stimulation of human endothelial cells [62]. Decreased
PAR-1 expression in response to inflammatory and
haemostatic stimuli might indicate a down-regulation of
inflammatory pathways in equine synovial fibroblasts.
VEGF was the only marker investigated, whose expres-
sion pattern was not changed in response to any of the
treatments. VEGF was initially expected to show increased
expression pattern in the stimulated synoviocytes, as it
has been demonstrated to have an angiogenic role in
inflammatory joint diseases [63] and has been found in
increased concentrations in synovial fluid of human
OA and RA patients [21, 64]. The angiogenic effects
and pro-inflammatory properties of VEGF in synovial
inflammation can potentially lead to hyperplasia of the
synovial membrane, pannus formation and development
of osteoarthritis [65, 66]. Several cell types such as rat
lung pericytes, human pancreatic stellate cells, human
fibroblast, human and bovine endothelial cells have
shown up-regulation of VEGF mRNA after LPS, thrombin
or fibrinogen treatment [25, 67–69]. While studies in
humans demonstrated increased VEGF concentrations in
synovial fluid from RA patients [21, 64], a study by Salvi et
al. [19] detected no change in VEGF expression in synovial
tissue from antigen-induced arthritis in mice. WhetherVEGF is consistently up-regulated in joint inflammation is
thus not clear at this stage and warrants further study.
This is the first study evaluating the relationship between
inflammation and haemostasis in equine fibroblast-like
synoviocytes. Obviously, the single cell type with exposure
to one inducing factor at a time cannot reflect the complex-
ity of events taking place in an inflamed joint, and further
studies are warranted before firm conclusions regarding the
interplay between inflammatory and haemostatic pathways
in equine joint disease may be drawn. However, the findings
of our study help elucidate specific interactions between in-
dividual reactants, which are otherwise impossible to tease
out of the complex microenvironment of the diseased joint.
In the present study, passage-4 equine synovial fibroblasts
were used. It is well documented that at this passage the
cell population is homogenous, because the culture envir-
onment does not favour the macrophage-like synoviocytes
[29, 30]. It is clear from the results of the present study that
it is important to include non-treated cell cultures at all in-
vestigated time points to control for culture-induced effects
on mRNA expression of the chosen markers unrelated to
the tested treatments. The non-treated cultures showed sig-
nificant increases in mRNA expression of SAA, MCP-1, TF,
VEGF and PAR-1 over time, showing that the culture envir-
onment affected the synoviocytes.
Conclusion
In conclusion, the results of this study indicate that in
equine fibroblast-like synoviocytes, inflammatory and
haemostatic pathways are at play simultaneously and
affect each other. All three treatments (LPS, fibrinogen
and thrombin) increased gene expression of inflammatory
markers. LPS treatment supported fibrinolysis, in contrast
fibrinogen and thrombin decreased fibrinolytic potential
of the fibroblast-like synoviocytes at mRNA level. Ini-
tiation of haemostasis in synoviocytes was affected in
opposing directions by LPS and fibrinogen, shown as
decreased and increased gene expression of TF, respect-
ively. The perspectives of these findings are a deeper un-
derstanding of events taking place in an inflamed joint.
Further studies with a closer clinical application are highly
needed to elucidate whether haemostasis plays a role in
equine joint inflammation corresponding to the current
understanding of human joint disease.
Methods
Sample population
Synovial membranes were collected from the dorsal and
palmar joint recesses of both metacarpo-phalangeal joints
of six skeletally mature (10 - 13 years old) horses of differ-
ent breeds euthanized for non-orthopaedic reasons at the
department of Veterinary Clinical and Animal Science,
University of Copenhagen according to regulations of
Danish law. Samples were harvested aseptically within
Andreassen et al. BMC Veterinary Research  (2015) 11:141 Page 9 of 121 h of euthanasia. The joints were macroscopically normal
and synovial fluid appeared normal in quantity, viscosity
and colour. Synovial tissue was pooled from both meta-
carpo-phalangeal joints of the same horse.
Isolation and culture of equine fibroblast-like
synoviocytes
Synoviocytes were isolated from the synovial tissue by
enzymatic digestion (1 mg/ml collagenase type 1 (Invi-
trogenTM, Life Technologies, Nærum, Denmark), 1 %
penicillin/streptomycin (InvitrogenTM), 1 % gentamycin
(InvitrogenTM) in Dulbecco’s Modified Eagle Medium
(DMEM) High Glucose (InvitrogenTM) for 3 h at 37 °C/
30 rpm. The released synoviocytes were centrifuged at
450 x g for 5 min, washed twice in sterile phosphate
buffered saline and cryopreserved with 10 % dimethyl
sulfoxide in foetal calf serum in liquid nitrogen until
study start.
The culture medium consisted of DMEM with addition
of 10 % foetal calf serum (InvitrogenTM), 5 ml penicillin
(100 IU/ml)/streptomycin (100 μg/ml), and 2.5 ml genta-
mycin (10 μg/ml).
At study start, the synoviocytes were thawed rapidly at
37 °C. After equalizing the cryopreserved synoviocytes
with culture medium, synoviocytes were rinsed twice with
culture medium to remove dimethyl sulfoxide remnants.Table 1 Equine specific primers used for quantitative real-time reve
Primer Primer sequence (5′→ 3′)
name Forward/reverse
SAA CCT GGG CTG CTA AAG TCA TC/
AGG CCA TGA GGT CTG AAG TG
IL-6 ATG GCA GAA AAA GAC GGA TG/
GGG TCA GGG GTG GTT ACT TC
MCP-1 ATT GGC CAA GGA GAT CTG TG/
ATA TCA GGG GGC ATT TAG GG
TF TGC ACT AGC CAA CAC AAA GC/
CAG AGA CAC AGC CAG GAT GA
uPA ATG TAT GGT GAT GCC CGT TT/
CAC AGC ATT TTG GTG GTG AC
PAI-1 AAG GGT CCG CTT CCT ACA AT/
TTG AAC TGC ATT GCC TCT TG
VEGF CAA CGA CGA GGG CCT AGA GT/
CAT CTC TCC TAT GTG TGG CTT TG
PAR1 TTC GTG ATA AGC CTG CCT CT/
GTA AAA CGC TGC AGT GAC GA
GAPDH GGG TGG AGC CAA AAG GGT CAT CAT/
AGC TTT CTC CAG GCG GCA GGT CAG
Primers used to amplify specific genes in LPS, fibrinogen, thrombin and non-treated
MCP-1: monocyte chemotactic protein-1. TF: tissue factor. uPA: urokinase plasminog
growth factor. PAR-1: protease activator receptor-1. GAPDH: gluceraldehyde‐3‐phosphaCells were seeded in monolayer cultures and cultured at
37 °C/5 % CO2 in a humidified atmosphere (passage 1).
Culture medium was aspirated after 24 h to remove non-
adherent synoviocytes. Culture medium was subsequently
changed every 48 to 72 h until synoviocytes reached
confluence, and upon confluence the synoviocytes were
passaged using 0.25 % trypsin/1 mM EDTA (InvitrogenTM).
Passage-4 synoviocytes were transferred to 24-well culture
plates at a density of 250,000 cells/well. Twenty-four hours
prior to stimulation the culture conditions were changed to
serum-free.
Experimental design
Initial experiments were conducted to establish concen-
tration and incubation time for the three stimulants:
LPS from Escherichia coli strain 055:B5 (# L2880,
Sigma-Aldrich Denmark ApS), plasminogen-depleted
fibrinogen (# 341578, Calbiochem, Merck, Darmstadt,
Germany) and thrombin (# T7572, Sigma-Aldrich
Denmark ApS) (data not shown). LPS was reconstituted
in sterile water and mixed with serum-free medium and
added directly to the wells in a concentration of 0.1 μg/ml
as previously described [70, 71]. Fibrinogen was recon-
stituted in 37 °C serum-free culture medium and added
directly to the wells in a concentration of 5 mg/ml as
previously described [11, 25, 30]. Thrombin wasrse transcriptase PCR
Product NCBI source/
size Reference
169 bp AF240364.1
220 bp [72]
166 bp EU779497.1
101 bp XM_001491449.2
175 bp XM_001502951.3
204 bp XM_001492517.3
100 bp [73]
212 bp XM_001503957.2
417 bp [74]
equine fibroblast-like synoviocytes: SAA: serum amyloid A. IL-6: interleukin-6.
en activator. PAI-1: plasminogen activator inhibitor-1. VEGF: vascular endothelial
te dehydrogenase
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vine serum albumin, mixed with serum-free culture
medium and added directly to the wells in a concentration
of 5 U/ml [14, 54]. Synoviocytes were harvested after 0, 6,
24, and 48 h of stimulation. Non-treated controls were
cultured in standard serum-free culture medium as de-
scribed above. All experiments were performed in duplicate
for each horse.
RNA isolation and quantitative real time reverse
transcriptase PCR analysis
Total RNA was extracted from the synoviocytes using the
Qiagen RNeasy Plus mini kit (Qiagen Nordic, Copenhagen
Ø, Denmark ). Cells were first homogenized through a
QIAshredder column for 2 min at 10,000 x g, and all
subsequent steps were performed as described in the
manufacturer’s manual. Resulting total RNA was quan-
tified by optical density measurement (NanoDrop TM
Spectrophotometer (Thermo Scientific, Wilmington, US)).
Twelve randomly selected samples were run in a bioanaly-
zer (Agilent 2100 Bioanalyzer (Agilent Technologies,
Hørsholm, Denmark)) to verify RNA quality. Total RNA
isolates were kept at -80 °C until further analysis.
cDNA was synthesized from 200 ng total RNA. The
reverse transcriptase PCR mastermix (Promega Biotech
AS, Nacka, Sweden) consisted of 5 μL RT buffer, 1.3 μL
dNTP mix (10 μM), 0.25 μL random hexamer primers
(2 μg/μL), 0.25 μL Oligo-dT primers (0.5 μg/μL), 0.8 μL
RNasin® Plus RNase inhibitor (40 U/μL), 1 μL M-MLV
Reverse Transcriptase (200 U/μL) and water. Reverse
transcription was performed in a BIOmetra® T-Gradient
thermocycler (Thermo scientific, Fisher Scientific,
Denmark) at 25 °C for 10 min, 42 °C for 60 min, and
95 °C for 5 min. Samples were stored at -20 °C.
Species-specific intron-spanning equine primers were
used to amplify SAA, IL-6, MCP-1, TF, uPA, PAI-1,
VEGF and PAR-1, and products were verified by gel
electrophoresis and sequencing. Primers are listed in
Table 1. Quantitative real time reverse transcriptase PCR
was performed in triplicates using the LightCycler® Fast
Start DNA Master SYBR Green I and LightCycler® Real-
Time PCR System (Roche, Hvidovre, Denmark).
Data analysis
Results were calculated using the efficiency corrected
calculation method also known as the Roche Applied
Sciences E(efficiency)-method:
Normalized relative ratio (NRR) = Et
CT (target calibrator) –
CT (target sample) / Er
CT (reference calibrator) – CT (reference sample)
[75].
All results were normalized to reference gene gluceral-
dehyde‐3‐phosphate dehydrogenase (GAPDH), selected
after initial testing of three reference genes (GAPDH,
β-actin and ribosomal RNA (18 S)).mRNA expression for each of the outcome parameters
was compared among treatments at the different time
points using a random intercept, random slope model in
R [76]. For each of the outcome parameters, the NRR
was log-transformed to achieve residuals (ε) which could
be deemed independent identically distributed Normal
(0, σ2) except for the parameter PAR-1, where a square
root transformation was used and for uPA, which was
not transformed at all. The general model used was thus:
transformation(NRR) = α + TX + time + TX x time + ε.
Where transformation(NRR) was the transformed
NRR for the specific outcome parameter (using the
transformations stated above), TX the fixed and random
effect of treatment (non-treated, fibrinogen, thrombin or
LPS treated), time the fixed and random effect of time,
and TX x time the interaction between time and TX.
Statistical significance was defined as p < 0.05 for all the
analyses. The results were presented as pairwise compar-
isons between treatments and non-treated within a time
point (6, 24 and 48 h) and all measurements were com-
pared to time point 0 h.
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